The first patient has been dosed in a Phase 2 extension study investigating the cancer vaccine DSP-7888 (ombipepimut-S) in combination with the checkpoint inhibitor Keytruda (pembrolizumab), in people with platinum-resistant ovarian cancer. The announcement follows promising data from the first portion of this Phase 1b/2 clinical trial (NCT03311334). The Phase 2 part is actively recruiting patients at sites across the United States. “Patients with platinum-resistant ovarian cancer have a high unmet need with limited treatment…
You must be logged in to read/download the full post.
The post First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer appeared first on BioNewsFeeds.